Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 6M | 248K | 15K | 17K |
| Gross Profit | -219K | 2M | 112K | 2K | 13K |
| Operating Income | -4M | 1M | -425K | -19K | -21K |
| EBITDA | -4M | 1M | -424K | -19K | -22K |
| Net Income | -4M | 1M | -425K | 7K | -22K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0111
+0.00% today
1Y Change
-98.89%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 251 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VitaSpring Biomedical Co. Ltd. (VSBC) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 98.9% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -431.1%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -431.1%, free cash flow -756.5% with operating margin 0.0% and ROIC 195.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VSBC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VSBC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VSBC Max Drawdown
-98.89%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VSBC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$17.2K
+13.5% YoY
FY Net Income
-$22.4K
-423.7% YoY
Free Cash Flow
-$34.2K
-32517.1% YoY
Revenue Growth
-100.0%
EPS Growth
-431.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 6M | 248K | 15K | 17K |
| Gross Profit | -219K | 2M | 112K | 2K | 13K |
| Operating Income | -4M | 1M | -425K | -19K | -21K |
| EBITDA | -4M | 1M | -424K | -19K | -22K |
| Net Income | -4M | 1M | -425K | 7K | -22K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30K | 107K | 45K | 0 | 105 |
| Total Assets | 766K | 4M | 189K | 0 | 11K |
| Total Liabilities | 3M | 2M | 93K | 0 | 18K |
| Shareholder Equity | -2M | 2M | 387K | -18K | -7K |
| Total Debt | 263K | 464K | 0 | 0 | 18K |
| Net Debt | 233K | 356K | -45K | 0 | 18K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
34K
-32517.1% YoY
Capital Expenditures
0
Free Cash Flow
34K
-32517.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
1017.0%
Debt / Equity
-0.11x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.